Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Japanese Journal of Ophthalmology 2026 Open access

Read full text
Authors: Masaru Inatani, Yuko Tone, Toshihiro Ikeda, Raymund Angeles
DOI: 10.1007/s10384-026-01351-2
Cited by: 1
References: 30

Abstract

PURPOSE: To evaluate the long-term safety and intraocular pressure (IOP)-lowering efficacy of sepetaprost, a novel dual FP/EP3 receptor agonist, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). STUDY DESIGN: ANGEL-J2 (NCT05503901) was a phase 3, randomised, parallel-group, open-label study across 20 sites in Japan. METHODS: Adult patients with IOP ≥16 and

Fields of Study & Subjects

Glaucoma and retinal disorders Retinal Diseases and Treatments Corneal surgery and disorders

Publication details

Journal / source
Japanese Journal of Ophthalmology
Publisher
Springer Science and Business Media LLC
Volume
70
Issue
4
Pages
940–948
Publication date
16 June 2026
Language
EN